Lung fluid immune cells may predict immunotherapy success

NCT ID NCT07331701

Not yet recruiting Knowledge-focused Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will examine immune cells found in fluid from the lungs of 60 people with advanced lung cancer. Researchers want to see if these cells can help predict how well standard cancer treatments work. Participants will have a bronchoscopy as part of their regular care, and the fluid collected will be analyzed for different types of immune cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to better ways to predict which lung cancer patients will respond to immunotherapy, improving treatment decisions.
What could go wrong: This is a small, early observational study, not a treatment trial. It may not find a clear link, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung carcinoma lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG NEOPLASMS TUMOR IMMUNE MICROENVIRONMENT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

SMG-SNU Boramae Medical Center

Seoul, Dongjak-gu, 07061, South Korea

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.